Barber Daniel sold $107K of AQST

Barber Daniel (President and CEO) sold 25,000 shares of Aquestive Therapeutics, Inc. (AQST) at $4.29 ($0.11M total) on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Barber Daniel
Published Aug 18, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AQST
Neutral
medium confidence
Mentioned
$AQST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

A CEO open-market sale under a 10b5-1 plan is typically a low-signal event for fundamentals, but it can influence short-term sentiment and positioning.

02

Market read

Traders may note the new insider-sale print, but there is no accompanying company-specific operational or financial catalyst in the text.

03

What to watch

The article does not state tax, diversification, or whether additional insider transactions occurred around the same period.

Relevance 3/10Novelty 4/10Timing: Filed 2026-08-18 after-hours; sale executed 2026-08-17.

Background

The article is a Form 4 insider transaction disclosure for Aquestive Therapeutics, Inc. (AQST).

Company-level read

Ticker impact

$AQSTNeutralMedium confidence
Context

Aquestive Therapeutics CEO Barber Daniel sold 25,000 shares in an open-market transaction at $4.2867 on 2026-08-17.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

Form 4 provides a fresh, time-stamped sale size and price, but the article does not include earnings, guidance, clinical, or regulatory catalysts.

Market effects

No sector-wide read-through is provided beyond a single biotech insider sale.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity management under a pre-arranged 10b5-1 plan, reducing signal value.

Key entities

  • Aquestive Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Barber Daniel

    President and CEO who sold 25,000 shares.

  • 10b5-1 plan

    Pre-arranged plan noted as Yes in the filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.